EMA Needs More Cases To Assess Value Of Involving Patients In CHMP Meetings
This article was originally published in SRA
Executive Summary
The European Medicines Agency is extending an ongoing pilot project in which it invites patients to take part in certain meetings that its human medicines committee, the CHMP, holds to discuss the benefits and risks of drugs.
You may also be interested in...
Pharma Firms Told To ‘Keep Your Distance’ When Patients Come To EU CHMP Meetings
The European Medicines Agency is planning to expand the involvement of patients in benefit-risk evaluation of medicines following a successful pilot, but one EU patient group has advised drug companies not to contact patients during their visits to the agency as this could lower the value of their input.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.